CapsoVision, Inc.
CV
Positions held
Your positionsCV isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $352.25M | Enterprise value | $322.92M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 25.17 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 9.9% | Earnings growth | — | Gross margin | 50.9% | Operating margin | -2.1% |
| Profit margin | -2.1% | ROE | -3.4% | ROA | -132.5% | Debt / equity | 0.05 |
| Current ratio | 3.35 | Free cash flow | -$16.28M | Analyst recommendation | strong_buy | Mean target | $9.50 |
| 52w high | $15.37 | 52w low | $4.38 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | $2.8M | $3.9M | $3.5M | $3.3M | — |
| Op margin | -208.1% | -254.0% | -190.5% | -226.7% | -140.3% | — |
| Net income | -$7.5M | -$7.0M | -$7.4M | -$7.9M | -$4.6M | — |
| Gross margin | 51.4% | 47.6% | 49.9% | 54.1% | 54.6% | — |
| Gross profit | $1.9M | $1.3M | $2.0M | $1.9M | $1.8M | — |
| Operating income | -$7.6M | -$7.1M | -$7.5M | -$8.0M | -$4.7M | — |
- Revenue +30% vs prior quarter ($3.6M vs $2.8M).
- Gross margin 51.4% (was 47.6% prior quarter).
- Operating margin expanded to -208.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $13.6M | $11.8M | $9.8M |
| Op margin | -188.3% | -169.4% | -116.3% |
| Net income | -$25.3M | -$19.9M | -$11.3M |
| Gross margin | 52.9% | 54.2% | 56.3% |
| Gross profit | $7.2M | $6.4M | $5.5M |
| Operating income | -$25.5M | -$19.9M | -$11.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
2026-09-24 · CapsoVision Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing
2026-09-21 · CapsoVision Insider Bought Shares Worth $4,999,996, According to a Recent SEC Filing
2026-09-03 · CapsoVision to Participate in Upcoming Investor Conferences
2026-08-27 · Outlook Therapeutics Appoints Kevin Lundquist as CFO
2026-08-14 · CapsoVision Inc (CV) (Q2 2026) Earnings Call Highlights: AI Launch Drives Growth Amid Pricing ...
2026-08-13 · CapsoVision Q2 Earnings Call Highlights
2026-08-13 · CapsoVision Files Mixed Shelf for Up to $250 Million in Securities
2026-08-13 · CapsoVision Reports Second Quarter 2026 Financial Results
2026-08-03 · CapsoVision® Announces International Launch of AI Highlights
2026-07-30 · CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
2026-07-23 · Visteon Announces Second Quarter 2026 Financial Results and $200 Million Accelerated Share Repurchase Program
Price (daily)
Full chart · RSI · MACD · patterns